BLCO Bausch + Lomb Corporation
USHealthcareAs of 2026-07-09 16:00
Why BLCO matters now
Bausch + Lomb Corporation (BLCO) is a US stock in Healthcare. The latest InvestLog snapshot shows $16.73 with +0.42% on the session and $5.96B in market capitalization; recent performance reads 1-month -8.21% and YTD -12.94%.
The latest financial table shown here is Q1 2026, with revenue of $1.24B, net income of $-71.0M, and EPS of $-0.20. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 0.1%.
The latest indexable market news headline is "Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate" from Business Wire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $19.00; recent insider activity includes Bonnefoy Luc filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.83
P/S
1.02
EV/EBITDA
15.57
DCF Value
$8.55
FCF Yield
0.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
55.9%
Operating Margin
5.9%
Net Margin
-4.2%
ROE
-3.4%
ROA
-1.6%
ROIC
2.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.24B | $-71.0M | $-0.20 |
| Q4 2025 | $1.41B | $-58.0M | $-0.16 |
| FY 2025 | $5.10B | $-360.0M | $-1.02 |
| Q3 2025 | $1.28B | $-28.0M | $-0.08 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$18.57
Target (Median)
$19.00
Target Range
$16.00 - $21.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
CA
Exchange
—
Beta
0.57
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.